Our Highly Experienced Executive Team has a Proven Track Record of Leadership, Global Registration and Lifecycle Management for Dozens of Biopharmaceutical Products.
Dr. Hillan has served on Achaogen’s board of directors since October 2011. Dr. Hillan joined Achaogen in April 2011 as Chief Medical Officer and was appointed Chief Executive Officer in October 2011. Dr. Hillan became President, R&D and President of Achaogen in January 2018. Prior to joining Achaogen, Dr. Hillan held leadership roles at Genentech (acquired by Roche in 2009) from August 1994 to April 2011. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. Dr. Hillan has served on the board of directors of Zymeworks, a publicly traded biotech company, since February 2017. He served on the board of directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
Ms. Bhatt joined Achaogen as Chief Business Officer in 2017. Ms. Bhatt brings to Achaogen more than 20 years of experience in corporate development and strategy in the biopharmaceutical industry. Most recently, Ms. Bhatt held the position of Vice President, Corporate Development at Gilead Sciences where she was responsible for executing licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas. While at Gilead, she also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Eli Lilly and Maxygen. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California at San Diego, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Ms. Dorling joined Achaogen as Chief Commercial Officer in 2017. Prior to Achaogen, Ms. Dorling spent 14 years at Genentech and Roche where, as Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech, she was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling lead hospital-focused Sales and Marketing teams that promoted Activase and Cathflo in the acute care setting. Ms. Dorling also had multiple roles with increasing responsibility in Market Analysis and Strategy in Ophthalmology, Oncology, and ultimately leading multiple functions with portfolio-wide responsibility. Prior to joining Genentech Ms. Dorling had several roles in Business Development at Altus Biologics, DNA Sciences, and Clontech Laboratories. Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master's in Science in Pharmacology and Cancer Biology from Duke University, and a Master's in Business Administration from the Haas School of Business at the University of California at Berkeley.
Ms. Larson joined Achaogen as Vice President, Technical Operations in 2016 and was promoted to Senior Vice President, Technical Operations in 2018. Prior to Achaogen, she spent 20 years at Genentech and Roche, holding leadership positions in Engineering, Manufacturing, and Technical Development. Recently as Global Head of Technical Development Business Operations at Roche, she led an organization accountable for developing and maintaining business and IT infrastructure for more than 2500 employees globally. Prior to that, as Genentech’s Senior Director of Technical Development Operations and Engineering, Ms. Larson oversaw multiple biopharmaceutical pilot manufacturing facilities, and supported the development and integration of innovative technologies to enhance/improve Genentech/Roche’s global manufacturing network. She also spent more than a decade as an Automation Engineer and Manufacturing Scientist. Ms. Larson worked on every commercial biopharmaceutical product launched from Genentech, and many clinical programs as well. In 2012, Ms. Larson was selected by the Genentech Executive Committee to be nationally recognized as their Healthcare Businesswomen’s Association Rising Star.
Ms. Larson has a Bachelor of Science in Chemical Engineering from Colorado State University. She currently serves on the Dean’s Advisory Board for the Walter Scott, Jr. College of Engineering at Colorado State University.
Dr. Swem was appointed Chief Scientific Officer in February 2017 and, prior to that, was the Vice President, Head of Research at Achaogen since 2015. Prior to this position, Dr. Swem spent just under two years as the Director of Achaogen’s Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem spent approximately four years as a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, he developed the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program. Under his leadership, the anti-influenza teams established an innovative human B cell enrichment and cloning technique to discover rare functional antibodies. This work led to the discovery of two broadly neutralizing antibodies targeting influenza A and influenza B.Dr. Swem served as the research lead on the anti-influenza development teams, which successfully transitioned the anti-influenza A antibody through Phase 1 and Phase 2 clinical trials and the anti-influenza B antibody into early development. The combination of these two human antibodies could constitute a therapy to treat all serious influenza infections. Prior to working at Genentech, Dr. Swem completed his postdoctoral work with Dr. Bonnie Bassler at Princeton University, where he successfully carried out multiple high-throughput screens to identify small molecule inhibitors of bacterial virulence cascades. Dr. Swem received his Ph.D. in microbiology from Indiana University.